doi: 10.1172/JCI11559.
Prevention of fat-induced insulin resistance by salicylate
Affiliations
- PMID:11489937
- PMCID: PMC209353
- DOI: 10.1172/JCI11559
Item in Clipboard
Prevention of fat-induced insulin resistance by salicylate
J K Kim et al. J Clin Invest.2001 Aug.
Display options
Format
Display options
Format
Abstract
Insulin resistance is a major factor in the pathogenesis of type 2 diabetes and may involve fat-induced activation of a serine kinase cascade involving IKK-beta. To test this hypothesis, we first examined insulin action and signaling in awake rats during hyperinsulinemic-euglycemic clamps after a lipid infusion with or without pretreatment with salicylate, a known inhibitor of IKK-beta. Whole-body glucose uptake and metabolism were estimated using [3-(3)H]glucose infusion, and glucose uptake in individual tissues was estimated using [1-(14)C]2-deoxyglucose injection during the clamp. Here we show that lipid infusion decreased insulin-stimulated glucose uptake and activation of IRS-1-associated PI 3-kinase in skeletal muscle but that salicylate pretreatment prevented these lipid-induced effects. To examine the mechanism of salicylate action, we studied the effects of lipid infusion on insulin action and signaling during the clamp in awake mice lacking IKK-beta. Unlike the response in wild-type mice, IKK-beta knockout mice did not exhibit altered skeletal muscle insulin signaling and action following lipid infusion. In summary, high-dose salicylate and inactivation of IKK-beta prevent fat-induced insulin resistance in skeletal muscle by blocking fat-induced defects in insulin signaling and action and represent a potentially novel class of therapeutic agents for type 2 diabetes.
Figures
Metabolic parameters and insulin-stimulated whole-body and skeletal muscle (soleus) glucose uptake in awake control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Plasma salicylate concentrations during basal and hyperinsulinemic-euglycemic clamp. (b) Plasma FFA concentrations during basal and hyperinsulinemic-euglycemic clamp. (c) Insulin-stimulated whole-body glucose uptake in vivo. (d) Insulin-stimulated skeletal muscle glucose uptake in vivo. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Insulin-stimulated whole-body and skeletal muscle (soleus) glucose metabolic flux in awake control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Insulin-stimulated whole-body glycolysis in vivo. (b) Insulin-stimulated whole-body glycogen/lipid synthesis in vivo. (c) Insulin-stimulated skeletal muscle glycolysis in vivo. (d) Insulin-stimulated skeletal muscle glycogen synthesis in vivo. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Insulin signaling in skeletal muscle (gastrocnemius) of the control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate (dark gray bars) rats. (a) Insulin-stimulated tyrosine phosphorylation of insulin receptor. (b) Insulin-stimulated tyrosine phosphorylation of IRS-1. (c) Insulin-stimulated IRS-1–associated PI 3-kinase activity. Values are means ± SE for six to seven experiments. *P < 0.05 versus control group.
Insulin action in liver and epididymal white adipose tissue in the control (black bars), salicylate (light gray bars), lipid (open bars), and lipid-salicylate rats (dark gray bars). (a) Basal rates of endogenous glucose production. (b) Percent suppression of basal endogenous glucose production during insulin-stimulated state. (c) Insulin-stimulated glucose uptake in epididymal white adipose tissue. Values are means ± SE for six to seven experiments.
Metabolic parameters and insulin-stimulated whole-body and skeletal muscle (gastrocnemius) glucose uptake in awake control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Plasma FFA concentrations during basal and hyperinsulinemic-euglycemic clamp. (b) Insulin-stimulated percent suppression of basal EGP. (c) Insulin-stimulated whole-body glucose uptake in vivo. (d) Insulin-stimulated skeletal muscle glucose uptake in vivo. Values are means ± SE for three to five experiments. *P < 0.05 versus control group;†P < 0.05 versus IKK-β KO-lipid group.
Insulin-stimulated whole-body and skeletal muscle (gastrocnemius) glucose metabolic flux in awake control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Insulin-stimulated whole-body glycolysis in vivo. (b) Insulin-stimulated whole-body glycogen/lipid synthesis in vivo. (c) Insulin-stimulated skeletal muscle glycolysis in vivo. (d) Insulin-stimulated skeletal muscle glycogen synthesis in vivo. Values are means ± SE for three to five experiments. *P < 0.05 versus control group;†P < 0.05 versus IKK-β KO-lipid group.
Insulin signaling in skeletal muscle (gastrocnemius) and insulin action in fat of the control (black bars), IKK-β KO (light gray bars), control-lipid (open bars), and IKK-β KO-lipid (dark gray bars) mice. (a) Insulin-stimulated tyrosine phosphorylation of IRS-1 in skeletal muscle. (b) Insulin-stimulated IRS-1–associated PI 3-kinase activity in skeletal muscle. (c) Insulin-stimulated glucose uptake in intrascapular brown adipose tissue. (d) Insulin-stimulated glucose uptake in epididymal white adipose tissue. Values are means ± SE for three to five experiments. *P < 0.05 versus control group;†P < 0.05 versus IKK-β KO-lipid group.
Comment in
- Turning down insulin signaling.Birnbaum MJ.Birnbaum MJ.J Clin Invest. 2001 Sep;108(5):655-9. doi: 10.1172/JCI13714.J Clin Invest. 2001.PMID:11544268Free PMC article.No abstract available.
- The effect of salicylates on insulin sensitivity.Netea MG, Tack CJ, Netten PM, Lutterman JA, Van der Meer JW.Netea MG, et al.J Clin Invest. 2001 Dec;108(11):1723-4. doi: 10.1172/JCI14455.J Clin Invest. 2001.PMID:11733568Free PMC article.No abstract available.
Similar articles
- Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes.Storgaard H, Jensen CB, Björnholm M, Song XM, Madsbad S, Zierath JR, Vaag AA.Storgaard H, et al.J Clin Endocrinol Metab. 2004 Mar;89(3):1301-11. doi: 10.1210/jc.2003-031243.J Clin Endocrinol Metab. 2004.PMID:15001626Clinical Trial.
- PKC-theta knockout mice are protected from fat-induced insulin resistance.Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O'Brien WR, Littman DR, Shulman GI.Kim JK, et al.J Clin Invest. 2004 Sep;114(6):823-7. doi: 10.1172/JCI22230.J Clin Invest. 2004.PMID:15372106Free PMC article.
- Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.Park E, Wong V, Guan X, Oprescu AI, Giacca A.Park E, et al.J Endocrinol. 2007 Nov;195(2):323-31. doi: 10.1677/JOE-07-0005.J Endocrinol. 2007.PMID:17951543
- Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.Højlund K.Højlund K.Dan Med J. 2014 Jul;61(7):B4890.Dan Med J. 2014.PMID:25123125Review.
- Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance.Shoelson SE, Lee J, Yuan M.Shoelson SE, et al.Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S49-52. doi: 10.1038/sj.ijo.0802501.Int J Obes Relat Metab Disord. 2003.PMID:14704745Review.
Cited by
- The Effect of Healthy Lifestyle Strategies on the Management of Insulin Resistance in Children and Adolescents with Obesity: A Narrative Review.Calcaterra V, Verduci E, Vandoni M, Rossi V, Fiore G, Massini G, Berardo C, Gatti A, Baldassarre P, Bianchi A, Cordaro E, Cavallo C, Cereda C, Bosetti A, Zuccotti G.Calcaterra V, et al.Nutrients. 2022 Nov 6;14(21):4692. doi: 10.3390/nu14214692.Nutrients. 2022.PMID:36364954Free PMC article.Review.
- Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?Mirrakhimov AE, Polotsky VY.Mirrakhimov AE, et al.Front Neurol. 2012 Oct 17;3:149. doi: 10.3389/fneur.2012.00149. eCollection 2012.Front Neurol. 2012.PMID:23087670Free PMC article.
- Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization.Nixon M, Wake DJ, Livingstone DE, Stimson RH, Esteves CL, Seckl JR, Chapman KE, Andrew R, Walker BR.Nixon M, et al.Diabetes. 2012 Apr;61(4):790-6. doi: 10.2337/db11-0931. Epub 2012 Feb 22.Diabetes. 2012.PMID:22357964Free PMC article.Clinical Trial.
- Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice.Ayala JE, Bracy DP, Malabanan C, James FD, Ansari T, Fueger PT, McGuinness OP, Wasserman DH.Ayala JE, et al.J Vis Exp. 2011 Nov 16;(57):3188. doi: 10.3791/3188.J Vis Exp. 2011.PMID:22126863Free PMC article.
- Insulin receptor and IRS-1 co-immunoprecipitation with SOCS-3, and IKKα/β phosphorylation are increased in obese Zucker rat skeletal muscle.Zolotnik IA, Figueroa TY, Yaspelkis BB 3rd.Zolotnik IA, et al.Life Sci. 2012 Oct 22;91(15-16):816-22. doi: 10.1016/j.lfs.2012.08.038. Epub 2012 Sep 13.Life Sci. 2012.PMID:22982470Free PMC article.
References
- DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687. - PubMed
- Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607. - PubMed
- Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10. - PubMed
- Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous